We then used long-term experimental evolution of each cell line under ribociclib to develop three paired cancer cell lines with joint endocrine and CDK4/6i resistance (evolved lines with combination ribociclib resistance (CRR)) (Grolmusz et al, 2020; Emond et al, 2023). This evidence concerns the gene CDK4 and cancer.